专门针对TNFR1的迷你绑定蛋白的设计
Jun Weng1, Miaomiao Geng2, Xiaoyu Hu2
1State Key Laboratory of Biocatalysis and Enzyme Engineering, School of Life Sciences, Hubei University, Wuhan, Hubei 430062, China; National & Local Joint Engineering Research Center of High-throughput Drug Screening Technology, School of Life Sciences, Hubei University, Wuhan, Hubei 430062, China; Key Laboratory of Molecular Biophysics of Ministry of Education, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, Hubei 430074, China.
针对TNFR1的新型迷你绑定蛋白为自身免疫性疾病的TNFα抑制剂提供了有希望的替代品,可能减少副作用. 一种迷你绑定剂S1B2在阻断TNFα信号传递方面具有很高的功效.
科学领域:
- 生物化学 生物化学
- 免疫学 免疫学 免疫学
- 药物发现 药物发现 药物发现
背景情况:
- 瘤坏死因子α (TNFα) 抑制剂对自身免疫性疾病有效,但具有感染和其他不良影响等风险.
- 选择性抑制TNFα受体1 (TNFR1) 信号传递是一种潜在的治疗策略,可以减轻这些风险.
- 开发TNFR1的新型抗体对于推进自身免疫性疾病治疗至关重要.
研究的目的:
- 设计和开发新的小型绑定蛋白质,可以选择性地抑制TNFR1信号传递.
- 为自身免疫性疾病创造一种新的治疗方法,其副作用可能比目前的TNFα抑制剂少.
- 确定一种分子,以作为TNFR1抗剂进一步开发.
主要方法:
- 针对TNFR1 (sTNFR1) 的可溶性外域的迷你绑定蛋白的新计算设计.
- 在大肠杆菌中选择和表达顶部设计的迷你结合剂.
- 在基于细胞的测试中,对迷你结合剂稳定性,对sTNFR1的亲和力和TNFα信号抑制的表征.
主要成果:
- 成功设计和表达了针对sTNFR1.1的迷你绑定蛋白.
- 纯化的迷你结合剂显示出对sTNFR1.1的热稳定性和微分子到亚微分子亲和力.
- 所有设计的迷你结合剂都有效地阻断了TNFα信号传递,其中一个候选物S1B2显示出高强度 (IC50 = 4.32 nM).
结论:
- 计算设计是开发TNFR1抗剂的有效方法.
- 迷你捆绑器S1B2表现出显著的功效,是进一步开发的有希望的首选.
- 这项工作通过选择性地准TNFR1信号传递,为自身免疫性疾病提供了一种新的治疗策略.
相关概念视频
Tail-anchoring of Proteins in the ER Membrane
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Conserved Binding Sites
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
TGF - β Signaling Pathway


